KaydedilenlerDerginizi ekleyin

Dergiler / Üroonkoloji Bülteni / 2018 / Cilt: 17 - Sayı: 2

Organ-Preserving Approach in Bladder Cancer: Assessment of the Current Situation

Mesane Kanserinde Organ Koruyucu Yaklaşım: Güncel Durum Değerlendirmesi

REHA GİRGİN
NECMETTİN AYDIN MUNGAN
Sayfa
63–67
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this review, current intravesical treatment alternatives to radical cystectomy in intravesical BCG failure are discussed with oncologic outcomes.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment option in high-risk non-invasive bladder cancer.
📊
Temel Bulgular & Veri:A significant proportion of patients have BCG intolerance after beginning intravesical treatment.
💡
Sonuç & Katkı:In this review, current intravesical treatment alternatives to radical cystectomy in intravesical BCG failure are discussed with oncologic outcomes.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment option in high-risk non-invasive bladder cancer. However, BCG is a very toxic agent. A significant proportion of patients have BCG intolerance after beginning intravesical treatment. Radical cystectomy is the recommended approach for patients with either BCG failure or BCG intolerance. Alternative intravesical salvage treatments are needed for patients who cannot tolerate radical cystectomy due to comorbidities or who refuse surgery. In this review, current intravesical treatment alternatives to radical cystectomy in intravesical BCG failure are discussed with oncologic outcomes.

Abstract

İntravezikal bacillus Calmette-Guérin (BCG) tedavisi yüksek riskli kasa invaze olmayan mesane kanserinde altın standart tedavi seçeneğidir. Bununla beraber BCG oldukça toksik bir ajandır. Tedaviye başladıktan sonra hastaların önemli bir kısmında BCG intoleransı izlenir. İster BCG başarısızlığı olsun, ister BCG intoleransı olsun radikal sistektomi bu aşamada önerilen tedavi yaklaşımı olmaktadır. Komorbiditeleri nedeniyle radikal sistektomiyi tolere edemeyecek ya da böylesi bir cerrahiyi kabul etmeyen hastalarda alternatif intravezikal kurtarma tedavilerine ihtiyaç vardır. Bu derlemede intravezikal BCG başarısızlığında radikal sistektomiye alternatif intravezikal güncel tedavi seçenekleri onkolojik sonuçlarıyla birlikte tartışılmıştır.

🔖

Bu Makaleye Atıf Yap

GİRGİN, R., MUNGAN, N. A. (2018). Organ-Preserving Approach in Bladder Cancer: Assessment of the Current Situation. Üroonkoloji Bülteni, Cilt: 17 - Sayı: 2, 63–67. https://ajindex.com/articles/334870

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. 2015. http://globocan.iarc.fr, accessed on day/month/year Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. Edward M. Messing. Bladder Sparing Therapy for BCG Failures – I - Intravesical Immunotherapy. Bladder Cancer 2017;3:313-314.
  2. Ahn JJ, Ghandour RA, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory nonmuscle invasive bladder cancer. Curr Opin Urol 2014;24:540-545.
  3. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124-1129.
  4. Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin. Eur Urol 2015;67:359-360.
  5. Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447-461.
  6. Alhogbani MM, Picard JA, Fassi-Fehri MH, et al. Prognostic impact of Bacillus Calmette-Guérin interruption at the time of induction and consolidation. Urol Ann 2017;9:315-320.
  7. Packiam VT, Johnson SC, Steinberg GD. Non-Muscle-Invasive Bladder Cancer: Intravesical Treatments Beyond Bacille Calmette-Guerin. Cancer 2017;123:390-400.
  8. Malmström PU, Wijkström H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish Norwegian Bladder Cancer Study Group. J Urol 1999;161:1124-1127.
  9. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: a systematic review. Eur Urol 2011;60:81-93.
  10. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermochemotherapy for recurrent bladder cancer after bacillus Calmette- Guerin. J Urol 2009;182:1313-1317.
  11. Witjes JA, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009;27:319-324.
  12. Zargar H, Aning J, Ischia J, et al. Optimizing intravesical mitomycin C therapy in nonmuscle-invasive bladder cancer. Nat Rev Uro